Coya Therapeutics, Inc. 8-K

What Happened
Coya Therapeutics (COYA) filed an 8-K (Jan 30, 2026) reporting a Securities Purchase Agreement entered Jan 29, 2026 to sell 2,522,727 shares of common stock at $4.40 per share in a private placement expected to raise approximately $11.1 million in gross proceeds. Purchasers include Dr. Reddy’s Laboratories ($10.0 million) and existing investor Greenlight Capital ($1.1 million). The closing was expected on or about Jan 30, 2026, subject to customary conditions, and the sale is being made under an exemption from registration (Section 4(a)(2)); the company agreed to file a registration statement covering resale of the shares within 45 days of closing and to have it declared effective no later than 75 days.

Key Details

• 2,522,727 shares of common stock to be issued at $4.40 per share; gross proceeds ≈ $11.1M.
• Purchasers: Dr. Reddy’s Labs ($10.0M) and Greenlight Capital ($1.1M).
• Use of proceeds: tech transfer and scale-up of low‑dose IL‑2 (LD IL‑2) manufacturing to support commercial readiness of COYA 302.
• Company reiterated cash runway guidance into the second half of 2027 and past the projected topline for the ALSTARS trial; press release issued Jan 30, 2026.

Why It Matters
This financing provides near‑term capital specifically earmarked for manufacturing and commercial readiness of COYA 302, helping the company advance plans without altering its stated cash runway guidance. Investors should note the participation of Dr. Reddy’s (a large pharma manufacturer) and that the shares are currently sold in an unregistered private placement with resale registration to be filed by the company. The filing also contains standard forward‑looking statement disclosures about risks and uncertainties.